# 30-Day Workflow Intelligence Sprint

## Proposed Engagement
- Status: sellable-now
- Duration: 30 days
- Recommended commercial model: Recommended fixed-fee range: $25k-$75k; mission-clinic access path $12.5k-$25k for one no-PHI workflow with capped artifacts
- Target buyer: Healthcare operators selecting the first high-value workflow for governed AI transformation
- Request route: /pilot?offer=workflow-intelligence-assessment

## Objective
Convert one to three fragmented workflows into a prioritized operating map, measurable value hypothesis, and governed pilot decision.

## Deliverables
- Current-state workflow and friction map
- Automation candidate scorecard
- Agent, reviewer, and interoperability responsibility map
- Baseline measurement plan
- Executive pilot recommendation

## Included Product Proof
- [CarePath Access Operations Demo](/demos/carepath-access-operations): Demonstrate how a fragmented high-risk follow-up queue becomes a reviewable operational routing packet.
- [DocuTwin Documentation Review Demo](/demos/docutwin-documentation-review): Demonstrate draft-only documentation support that preserves authorship, source trace, missing context, and review control.
- [AgentOS Governance Evaluation Demo](/demos/agentos-governance-evaluation): Demonstrate how a synthetic enterprise workflow packet becomes a governed multi-agent plan and Atlas Trust Card.

## Decision Metrics
- Priority workflow approved
- Baseline and target metrics defined
- Governance gaps assigned owners
- Pilot scope and decision criteria approved

## Buyer Inputs
- Executive or operational sponsor
- One to three workflow descriptions without PHI
- Current friction and handoff context
- Governance and interoperability requirements

## Governance Gates
- No PHI or patient-level records
- Human-review operating model defined
- Synthetic evidence scope approved
- Production requirements listed separately

## Production Exclusions
- No live workflow integration
- No autonomous action
- No production data processing
- No clinical outcome claim

## Product Boundary
SCRIMED demos and pilot programs are governed synthetic evaluations for enterprise buyers. They do not ingest live PHI, diagnose, treat, submit payer transactions, contact patients, mutate production records, or autonomously execute clinical care.

This non-binding proposal is a starting point for enterprise scoping. Final scope, pricing, security requirements, legal terms, success criteria, and production permissions require written buyer and SCRIMED approval.